APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Pan-cancer Genomic Profiling

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Pan-cancer Genomic Profiling Market Outlook and Growth Opportunities 2026

Report ID 174522040412 August 2026201 pages

Choose your research edition.

Industry ResearchPan-cancer Genomic Profiling Industry Research Report 2026130 pages · $2,950 USDIndustry Growth & TrendsGlobal Pan-cancer Genomic Profiling Industry Growth and Trends Forecast to 2032114 pages · $3,450 USDMarket StructureGlobal Pan-cancer Genomic Profiling Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Pan-cancer Genomic Profiling Market Outlook and Growth Opportunities 2026201 pages · $4,250 USDMarket Analysis & ForecastGlobal Pan-cancer Genomic Profiling Market Analysis and Forecast 2026-2032181 pages · $4,950 USD

Market perspective

The global Pan-cancer Genomic Profiling market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Pan-cancer Genomic Profiling is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Pan-cancer Genomic Profiling is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Pan-cancer Genomic Profiling is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Pan-cancer Genomic Profiling market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Pan-cancer Genomic Profiling market include Tempus AI, Labcorp, NeoGenomics, Exact Sciences, Personalis, Illumina, Thermo Fisher Scientific, QIAGEN and Agilent Technologies, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Pan-cancer Genomic Profiling market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Pan-cancer Genomic Profiling and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Pan-cancer Genomic Profiling revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Pan-cancer Genomic Profiling market.

Pan-cancer Genomic Profiling Segment by Company

Tempus AI

Labcorp

NeoGenomics

Exact Sciences

Personalis

Illumina

Thermo Fisher Scientific

QIAGEN

Agilent Technologies

SOPHiA GENETICS

Sysmex

Burning Rock Biotech

Genetron Health

Geneseeq

BGI Genomics

Amoy Diagnostics

Roche

Guardant Health

Caris Life Sciences

Pan-cancer Genomic Profiling Segment by Type

Tissue-based Profiling

Liquid Biopsy Profiling

Other

Pan-cancer Genomic Profiling Segment by Application

Hospitals and Cancer Centers

Independent Clinical Laboratories

Pharmaceutical and Biotechnology Companies

Other

Pan-cancer Genomic Profiling Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Pan-cancer Genomic Profiling status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Pan-cancer Genomic Profiling key companies, revenue, market share, and recent developments.

3. To split the Pan-cancer Genomic Profiling breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Pan-cancer Genomic Profiling market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Pan-cancer Genomic Profiling significant trends, drivers, influence factors in global and regions.

6. To analyze Pan-cancer Genomic Profiling competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Pan-cancer Genomic Profiling market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Pan-cancer Genomic Profiling and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Pan-cancer Genomic Profiling.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Pan-cancer Genomic Profiling industry.

Chapter 3: Detailed analysis of Pan-cancer Genomic Profiling company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Pan-cancer Genomic Profiling in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Pan-cancer Genomic Profiling in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Pan-cancer Genomic Profiling Industry Trends Table 2. Pan-cancer Genomic Profiling Industry Drivers Table 3. Pan-cancer Genomic Profiling Industry Opportunities and Challenges Table 4. Pan-cancer Genomic Profiling Industry Restraints Table 5. Global Pan-cancer Genomic Profiling Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Pan-cancer Genomic Profiling Revenue Share by Company (2021-2026) Table 7. Global Pan-cancer Genomic Profiling Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Pan-cancer Genomic Profiling Key Company Manufacturing Base & Headquarters Table 9. Global Pan-cancer Genomic Profiling Company, Product Type & Application Table 10. Global Pan-cancer Genomic Profiling Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Pan-cancer Genomic Profiling by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Tissue-based Profiling Table 15. Significant Companies of Liquid Biopsy Profiling Table 16. Significant Companies of Other Table 17. Global Pan-cancer Genomic Profiling Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 18. Global Pan-cancer Genomic Profiling Sales Value by Type (2021-2026) & (US$ Million) Table 19. Global Pan-cancer Genomic Profiling Sales Value by Type (2027-2032) & (US$ Million) Table 20. Global Pan-cancer Genomic Profiling Sales Value Share by Type (2021-2026) Table 21. Global Pan-cancer Genomic Profiling Sales Value Share by Type (2027-2032) Table 22. Significant Companies of Hospitals and Cancer Centers Table 23. Significant Companies of Independent Clinical Laboratories Table 24. Significant Companies of Pharmaceutical and Biotechnology Companies Table 25. Significant Companies of Other Table 26. Global Pan-cancer Genomic Profiling Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Pan-cancer Genomic Profiling Sales Value by Application (2021-2026) & (US$ Million) Table 28. Global Pan-cancer Genomic Profiling Sales Value by Application (2027-2032) & (US$ Million) Table 29. Global Pan-cancer Genomic Profiling Sales Value Share by Application (2021-2026) Table 30. Global Pan-cancer Genomic Profiling Sales Value Share by Application (2027-2032) Table 31. Global Pan-cancer Genomic Profiling Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Pan-cancer Genomic Profiling Sales Value by Region (2021-2026) & (US$ Million) Table 33. Global Pan-cancer Genomic Profiling Sales Value Share by Region (2021-2026) Table 34. Global Pan-cancer Genomic Profiling Sales Value by Region (2027-2032) & (US$ Million) Table 35. Global Pan-cancer Genomic Profiling Sales Value Share by Region (2027-2032) Table 36. Global Pan-cancer Genomic Profiling Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Pan-cancer Genomic Profiling Sales Value by Country (2021-2026) & (US$ Million) Table 38. Global Pan-cancer Genomic Profiling Sales Value Market Share by Country (2021-2026) Table 39. Global Pan-cancer Genomic Profiling Sales Value by Country (2027-2032) & (US$ Million) Table 40. Global Pan-cancer Genomic Profiling Sales Value Market Share by Country (2027-2032) Table 41. Tempus AI Company Information Table 42. Tempus AI Business Overview Table 43. Tempus AI Pan-cancer Genomic Profiling Revenue (US$ Million) and Gross Margin (2021-2026) Table 44. Tempus AI Pan-cancer Genomic Profiling Product Portfolio Table 45. Tempus AI Recent Development Table 46. Labcorp Company Information Table 47. Labcorp Business Overview Table 48. Labcorp Pan-cancer Genomic Profiling Revenue (US$ Million) and Gross Margin (2021-2026) Table 49. Labcorp Pan-cancer Genomic Profiling Product Portfolio Table 50. Labcorp Recent Development Table 51. NeoGenomics Company Information Table 52. NeoGenomics Business Overview Table 53. NeoGenomics Pan-cancer Genomic Profiling Revenue (US$ Million) and Gross Margin (2021-2026) Table 54. NeoGenomics Pan-cancer Genomic Profiling Product Portfolio Table 55. NeoGenomics Recent Development Table 56. Exact Sciences Company Information Table 57. Exact Sciences Business Overview Table 58. Exact Sciences Pan-cancer Genomic Profiling Revenue (US$ Million) and Gross Margin (2021-2026) Table 59. Exact Sciences Pan-cancer Genomic Profiling Product Portfolio Table 60. Exact Sciences Recent Development Table 61. Personalis Company Information Table 62. Personalis Business Overview Table 63. Personalis Pan-cancer Genomic Profiling Revenue (US$ Million) and Gross Margin (2021-2026) Table 64. Personalis Pan-cancer Genomic Profiling Product Portfolio Table 65. Personalis Recent Development Table 66. Illumina Company Information Table 67. Illumina Business Overview Table 68. Illumina Pan-cancer Genomic Profiling Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. Illumina Pan-cancer Genomic Profiling Product Portfolio Table 70. Illumina Recent Development Table 71. Thermo Fisher Scientific Company Information Table 72. Thermo Fisher Scientific Business Overview Table 73. Thermo Fisher Scientific Pan-cancer Genomic Profiling Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. Thermo Fisher Scientific Pan-cancer Genomic Profiling Product Portfolio Table 75. Thermo Fisher Scientific Recent Development Table 76. QIAGEN Company Information Table 77. QIAGEN Business Overview Table 78. QIAGEN Pan-cancer Genomic Profiling Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. QIAGEN Pan-cancer Genomic Profiling Product Portfolio Table 80. QIAGEN Recent Development Table 81. Agilent Technologies Company Information Table 82. Agilent Technologies Business Overview Table 83. Agilent Technologies Pan-cancer Genomic Profiling Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. Agilent Technologies Pan-cancer Genomic Profiling Product Portfolio Table 85. Agilent Technologies Recent Development Table 86. SOPHiA GENETICS Company Information Table 87. SOPHiA GENETICS Business Overview Table 88. SOPHiA GENETICS Pan-cancer Genomic Profiling Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. SOPHiA GENETICS Pan-cancer Genomic Profiling Product Portfolio Table 90. SOPHiA GENETICS Recent Development Table 91. Sysmex Company Information Table 92. Sysmex Business Overview Table 93. Sysmex Pan-cancer Genomic Profiling Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 94. Sysmex Pan-cancer Genomic Profiling Product Portfolio Table 95. Sysmex Recent Development Table 96. Burning Rock Biotech Company Information Table 97. Burning Rock Biotech Business Overview Table 98. Burning Rock Biotech Pan-cancer Genomic Profiling Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 99. Burning Rock Biotech Pan-cancer Genomic Profiling Product Portfolio Table 100. Burning Rock Biotech Recent Development Table 101. Genetron Health Company Information Table 102. Genetron Health Business Overview Table 103. Genetron Health Pan-cancer Genomic Profiling Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 104. Genetron Health Pan-cancer Genomic Profiling Product Portfolio Table 105. Genetron Health Recent Development Table 106. Geneseeq Company Information Table 107. Geneseeq Business Overview Table 108. Geneseeq Pan-cancer Genomic Profiling Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 109. Geneseeq Pan-cancer Genomic Profiling Product Portfolio Table 110. Geneseeq Recent Development Table 111. BGI Genomics Company Information Table 112. BGI Genomics Business Overview Table 113. BGI Genomics Pan-cancer Genomic Profiling Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 114. BGI Genomics Pan-cancer Genomic Profiling Product Portfolio Table 115. BGI Genomics Recent Development Table 116. Amoy Diagnostics Company Information Table 117. Amoy Diagnostics Business Overview Table 118. Amoy Diagnostics Pan-cancer Genomic Profiling Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 119. Amoy Diagnostics Pan-cancer Genomic Profiling Product Portfolio Table 120. Amoy Diagnostics Recent Development Table 121. Roche Company Information Table 122. Roche Business Overview Table 123. Roche Pan-cancer Genomic Profiling Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 124. Roche Pan-cancer Genomic Profiling Product Portfolio Table 125. Roche Recent Development Table 126. Guardant Health Company Information Table 127. Guardant Health Business Overview Table 128. Guardant Health Pan-cancer Genomic Profiling Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 129. Guardant Health Pan-cancer Genomic Profiling Product Portfolio Table 130. Guardant Health Recent Development Table 131. Caris Life Sciences Company Information Table 132. Caris Life Sciences Business Overview Table 133. Caris Life Sciences Pan-cancer Genomic Profiling Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 134. Caris Life Sciences Pan-cancer Genomic Profiling Product Portfolio Table 135. Caris Life Sciences Recent Development Table 136. Research Programs/Design for This Report Table 137. Authors List of This Report Table 138. Secondary Sources Table 139. Primary Sources List of Figures Figure 1. Pan-cancer Genomic Profiling Product Image Figure 2. Global Pan-cancer Genomic Profiling Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Pan-cancer Genomic Profiling Market Size (2021-2032) & (US$ Million) Figure 4. Global Pan-cancer Genomic Profiling Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Tissue-based Profiling Image Figure 8. Liquid Biopsy Profiling Image Figure 9. Other Image Figure 10. Global Pan-cancer Genomic Profiling Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 11. Global Pan-cancer Genomic Profiling Sales Value Share 2021 VS 2025 VS 2032 Figure 12. Global Pan-cancer Genomic Profiling Sales Value Share by Type (2021-2032) Figure 13. Hospitals and Cancer Centers Image Figure 14. Independent Clinical Laboratories Image Figure 15. Pharmaceutical and Biotechnology Companies Image Figure 16. Other Image Figure 17. Global Pan-cancer Genomic Profiling Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Pan-cancer Genomic Profiling Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global Pan-cancer Genomic Profiling Sales Value Share by Application (2021-2032) Figure 20. Global Pan-cancer Genomic Profiling Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 21. Global Pan-cancer Genomic Profiling Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 22. North America Pan-cancer Genomic Profiling Sales Value (2021-2032) & (US$ Million) Figure 23. North America Pan-cancer Genomic Profiling Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Europe Pan-cancer Genomic Profiling Sales Value (2021-2032) & (US$ Million) Figure 25. Europe Pan-cancer Genomic Profiling Sales Value Share by Country (%), 2025 VS 2032 Figure 26. Asia-Pacific Pan-cancer Genomic Profiling Sales Value (2021-2032) & (US$ Million) Figure 27. Asia-Pacific Pan-cancer Genomic Profiling Sales Value Share by Country (%), 2025 VS 2032 Figure 28. South America Pan-cancer Genomic Profiling Sales Value (2021-2032) & (US$ Million) Figure 29. South America Pan-cancer Genomic Profiling Sales Value Share by Country (%), 2025 VS 2032 Figure 30. Middle East & Africa Pan-cancer Genomic Profiling Sales Value (2021-2032) & (US$ Million) Figure 31. Middle East & Africa Pan-cancer Genomic Profiling Sales Value Share by Country (%), 2025 VS 2032 Figure 32. USA Pan-cancer Genomic Profiling Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 33. USA Pan-cancer Genomic Profiling Sales Value Share by Type, 2025 VS 2032 & (%) Figure 34. USA Pan-cancer Genomic Profiling Sales Value Share by Application, 2025 VS 2032 & (%) Figure 35. Canada Pan-cancer Genomic Profiling Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. Canada Pan-cancer Genomic Profiling Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. Canada Pan-cancer Genomic Profiling Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Mexico Pan-cancer Genomic Profiling Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Mexico Pan-cancer Genomic Profiling Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Mexico Pan-cancer Genomic Profiling Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. Germany Pan-cancer Genomic Profiling Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. Germany Pan-cancer Genomic Profiling Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. Germany Pan-cancer Genomic Profiling Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. France Pan-cancer Genomic Profiling Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. France Pan-cancer Genomic Profiling Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. France Pan-cancer Genomic Profiling Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. U.K. Pan-cancer Genomic Profiling Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. U.K. Pan-cancer Genomic Profiling Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. U.K. Pan-cancer Genomic Profiling Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Italy Pan-cancer Genomic Profiling Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Italy Pan-cancer Genomic Profiling Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Italy Pan-cancer Genomic Profiling Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Spain Pan-cancer Genomic Profiling Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Spain Pan-cancer Genomic Profiling Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Spain Pan-cancer Genomic Profiling Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Russia Pan-cancer Genomic Profiling Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Russia Pan-cancer Genomic Profiling Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Russia Pan-cancer Genomic Profiling Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Netherlands Pan-cancer Genomic Profiling Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Netherlands Pan-cancer Genomic Profiling Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Netherlands Pan-cancer Genomic Profiling Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Nordic Countries Pan-cancer Genomic Profiling Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Nordic Countries Pan-cancer Genomic Profiling Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Nordic Countries Pan-cancer Genomic Profiling Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. China Pan-cancer Genomic Profiling Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. China Pan-cancer Genomic Profiling Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. China Pan-cancer Genomic Profiling Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Japan Pan-cancer Genomic Profiling Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Japan Pan-cancer Genomic Profiling Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Japan Pan-cancer Genomic Profiling Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. South Korea Pan-cancer Genomic Profiling Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. South Korea Pan-cancer Genomic Profiling Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. South Korea Pan-cancer Genomic Profiling Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. India Pan-cancer Genomic Profiling Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. India Pan-cancer Genomic Profiling Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. India Pan-cancer Genomic Profiling Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Australia Pan-cancer Genomic Profiling Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Australia Pan-cancer Genomic Profiling Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Australia Pan-cancer Genomic Profiling Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Southeast Asia Pan-cancer Genomic Profiling Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Southeast Asia Pan-cancer Genomic Profiling Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Southeast Asia Pan-cancer Genomic Profiling Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Brazil Pan-cancer Genomic Profiling Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Brazil Pan-cancer Genomic Profiling Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Brazil Pan-cancer Genomic Profiling Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Argentina Pan-cancer Genomic Profiling Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Argentina Pan-cancer Genomic Profiling Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Argentina Pan-cancer Genomic Profiling Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Chile Pan-cancer Genomic Profiling Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Chile Pan-cancer Genomic Profiling Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Chile Pan-cancer Genomic Profiling Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Colombia Pan-cancer Genomic Profiling Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Colombia Pan-cancer Genomic Profiling Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Colombia Pan-cancer Genomic Profiling Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Peru Pan-cancer Genomic Profiling Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Peru Pan-cancer Genomic Profiling Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Peru Pan-cancer Genomic Profiling Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Pan-cancer Genomic Profiling Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Saudi Arabia Pan-cancer Genomic Profiling Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Saudi Arabia Pan-cancer Genomic Profiling Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Israel Pan-cancer Genomic Profiling Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Israel Pan-cancer Genomic Profiling Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Israel Pan-cancer Genomic Profiling Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. UAE Pan-cancer Genomic Profiling Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. UAE Pan-cancer Genomic Profiling Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. UAE Pan-cancer Genomic Profiling Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Turkey Pan-cancer Genomic Profiling Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Turkey Pan-cancer Genomic Profiling Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Turkey Pan-cancer Genomic Profiling Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Iran Pan-cancer Genomic Profiling Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Iran Pan-cancer Genomic Profiling Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Iran Pan-cancer Genomic Profiling Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Egypt Pan-cancer Genomic Profiling Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Egypt Pan-cancer Genomic Profiling Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Egypt Pan-cancer Genomic Profiling Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Years Considered Figure 117. Research Process Figure 118. Key Executives Interviewed

Scope & coverage.

Types
  • Tissue-based Profiling
  • Liquid Biopsy Profiling
  • Other
Applications
  • Hospitals and Cancer Centers
  • Independent Clinical Laboratories
  • Pharmaceutical and Biotechnology Companies
  • Other
Companies covered
  • Tempus AI
  • Labcorp
  • NeoGenomics
  • Exact Sciences
  • Personalis
  • Illumina
  • Thermo Fisher Scientific
  • QIAGEN
  • Agilent Technologies
  • SOPHiA GENETICS
  • Sysmex
  • Burning Rock Biotech
  • Genetron Health
  • Geneseeq
  • BGI Genomics
  • Amoy Diagnostics
  • Roche
  • Guardant Health
  • Caris Life Sciences

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Pan-cancer Genomic Profiling Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Pan-cancer Genomic Profiling Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Pan-cancer Genomic Profiling Market Dynamics
  1. 2.1 Pan-cancer Genomic Profiling Industry Trends
  2. 2.2 Pan-cancer Genomic Profiling Industry Drivers
  3. 2.3 Pan-cancer Genomic Profiling Industry Opportunities and Challenges
  4. 2.4 Pan-cancer Genomic Profiling Industry Restraints
3 Pan-cancer Genomic Profiling Market by Company
  1. 3.1 Global Pan-cancer Genomic Profiling Company Revenue Ranking in 2025
  2. 3.2 Global Pan-cancer Genomic Profiling Revenue by Company (2021-2026)
  3. 3.3 Global Pan-cancer Genomic Profiling Company Ranking (2024-2026)
  4. 3.4 Global Pan-cancer Genomic Profiling Company Manufacturing Base and Headquarters
  5. 3.5 Global Pan-cancer Genomic Profiling Company Product Type and Application
  6. 3.6 Global Pan-cancer Genomic Profiling Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Pan-cancer Genomic Profiling Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Pan-cancer Genomic Profiling Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Pan-cancer Genomic Profiling Market by Type
  1. 4.1 Pan-cancer Genomic Profiling Type Introduction
  2. 4.1.1 Tissue-based Profiling
  3. 4.1.2 Liquid Biopsy Profiling
  4. 4.1.3 Other
  5. 4.2 Global Pan-cancer Genomic Profiling Sales Value by Type
  6. 4.2.1 Global Pan-cancer Genomic Profiling Sales Value by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Pan-cancer Genomic Profiling Sales Value by Type (2021-2032)
  8. 4.2.3 Global Pan-cancer Genomic Profiling Sales Value Share by Type (2021-2032)
5 Pan-cancer Genomic Profiling Market by Application
  1. 5.1 Pan-cancer Genomic Profiling Application Introduction
  2. 5.1.1 Hospitals and Cancer Centers
  3. 5.1.2 Independent Clinical Laboratories
  4. 5.1.3 Pharmaceutical and Biotechnology Companies
  5. 5.1.4 Other
  6. 5.2 Global Pan-cancer Genomic Profiling Sales Value by Application
  7. 5.2.1 Global Pan-cancer Genomic Profiling Sales Value by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Pan-cancer Genomic Profiling Sales Value by Application (2021-2032)
  9. 5.2.3 Global Pan-cancer Genomic Profiling Sales Value Share by Application (2021-2032)
6 Pan-cancer Genomic Profiling Regional Value Analysis
  1. 6.1 Global Pan-cancer Genomic Profiling Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Pan-cancer Genomic Profiling Sales Value by Region (2021-2032)
  3. 6.2.1 Global Pan-cancer Genomic Profiling Sales Value by Region: 2021-2026
  4. 6.2.2 Global Pan-cancer Genomic Profiling Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Pan-cancer Genomic Profiling Sales Value (2021-2032)
  7. 6.3.2 North America Pan-cancer Genomic Profiling Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Pan-cancer Genomic Profiling Sales Value (2021-2032)
  10. 6.4.2 Europe Pan-cancer Genomic Profiling Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Pan-cancer Genomic Profiling Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Pan-cancer Genomic Profiling Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Pan-cancer Genomic Profiling Sales Value (2021-2032)
  16. 6.6.2 South America Pan-cancer Genomic Profiling Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Pan-cancer Genomic Profiling Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Pan-cancer Genomic Profiling Sales Value Share by Country, 2025 VS 2032
7 Pan-cancer Genomic Profiling Country-level Value Analysis
  1. 7.1 Global Pan-cancer Genomic Profiling Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Pan-cancer Genomic Profiling Sales Value by Country (2021-2032)
  3. 7.2.1 Global Pan-cancer Genomic Profiling Sales Value by Country (2021-2026)
  4. 7.2.2 Global Pan-cancer Genomic Profiling Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Pan-cancer Genomic Profiling Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Pan-cancer Genomic Profiling Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Pan-cancer Genomic Profiling Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Pan-cancer Genomic Profiling Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Pan-cancer Genomic Profiling Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Pan-cancer Genomic Profiling Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Pan-cancer Genomic Profiling Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Pan-cancer Genomic Profiling Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Pan-cancer Genomic Profiling Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Pan-cancer Genomic Profiling Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Pan-cancer Genomic Profiling Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Pan-cancer Genomic Profiling Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Pan-cancer Genomic Profiling Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Pan-cancer Genomic Profiling Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Pan-cancer Genomic Profiling Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Pan-cancer Genomic Profiling Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Pan-cancer Genomic Profiling Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Pan-cancer Genomic Profiling Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Pan-cancer Genomic Profiling Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Pan-cancer Genomic Profiling Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Pan-cancer Genomic Profiling Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Pan-cancer Genomic Profiling Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Pan-cancer Genomic Profiling Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Pan-cancer Genomic Profiling Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Pan-cancer Genomic Profiling Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Pan-cancer Genomic Profiling Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Pan-cancer Genomic Profiling Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Pan-cancer Genomic Profiling Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Pan-cancer Genomic Profiling Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Pan-cancer Genomic Profiling Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Pan-cancer Genomic Profiling Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Pan-cancer Genomic Profiling Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Pan-cancer Genomic Profiling Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Pan-cancer Genomic Profiling Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Pan-cancer Genomic Profiling Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Pan-cancer Genomic Profiling Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Pan-cancer Genomic Profiling Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Pan-cancer Genomic Profiling Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Pan-cancer Genomic Profiling Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Pan-cancer Genomic Profiling Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Pan-cancer Genomic Profiling Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Pan-cancer Genomic Profiling Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Pan-cancer Genomic Profiling Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Pan-cancer Genomic Profiling Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Pan-cancer Genomic Profiling Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Pan-cancer Genomic Profiling Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Pan-cancer Genomic Profiling Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Pan-cancer Genomic Profiling Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Pan-cancer Genomic Profiling Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Pan-cancer Genomic Profiling Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Pan-cancer Genomic Profiling Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Pan-cancer Genomic Profiling Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Pan-cancer Genomic Profiling Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Pan-cancer Genomic Profiling Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Pan-cancer Genomic Profiling Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Pan-cancer Genomic Profiling Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Pan-cancer Genomic Profiling Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Pan-cancer Genomic Profiling Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Pan-cancer Genomic Profiling Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Pan-cancer Genomic Profiling Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Pan-cancer Genomic Profiling Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Pan-cancer Genomic Profiling Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Pan-cancer Genomic Profiling Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Pan-cancer Genomic Profiling Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Pan-cancer Genomic Profiling Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Pan-cancer Genomic Profiling Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Pan-cancer Genomic Profiling Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Pan-cancer Genomic Profiling Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Pan-cancer Genomic Profiling Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Pan-cancer Genomic Profiling Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Pan-cancer Genomic Profiling Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Pan-cancer Genomic Profiling Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Pan-cancer Genomic Profiling Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Pan-cancer Genomic Profiling Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Pan-cancer Genomic Profiling Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Pan-cancer Genomic Profiling Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Pan-cancer Genomic Profiling Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Pan-cancer Genomic Profiling Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Pan-cancer Genomic Profiling Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Pan-cancer Genomic Profiling Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Pan-cancer Genomic Profiling Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Pan-cancer Genomic Profiling Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Pan-cancer Genomic Profiling Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Pan-cancer Genomic Profiling Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Tempus AI
  2. 8.1.1 Tempus AI Company Information
  3. 8.1.2 Tempus AI Business Overview
  4. 8.1.3 Tempus AI Pan-cancer Genomic Profiling Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Tempus AI Pan-cancer Genomic Profiling Product Portfolio
  6. 8.1.5 Tempus AI Recent Developments
  7. 8.2 Labcorp
  8. 8.2.1 Labcorp Company Information
  9. 8.2.2 Labcorp Business Overview
  10. 8.2.3 Labcorp Pan-cancer Genomic Profiling Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Labcorp Pan-cancer Genomic Profiling Product Portfolio
  12. 8.2.5 Labcorp Recent Developments
  13. 8.3 NeoGenomics
  14. 8.3.1 NeoGenomics Company Information
  15. 8.3.2 NeoGenomics Business Overview
  16. 8.3.3 NeoGenomics Pan-cancer Genomic Profiling Revenue and Gross Margin (2021-2026)
  17. 8.3.4 NeoGenomics Pan-cancer Genomic Profiling Product Portfolio
  18. 8.3.5 NeoGenomics Recent Developments
  19. 8.4 Exact Sciences
  20. 8.4.1 Exact Sciences Company Information
  21. 8.4.2 Exact Sciences Business Overview
  22. 8.4.3 Exact Sciences Pan-cancer Genomic Profiling Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Exact Sciences Pan-cancer Genomic Profiling Product Portfolio
  24. 8.4.5 Exact Sciences Recent Developments
  25. 8.5 Personalis
  26. 8.5.1 Personalis Company Information
  27. 8.5.2 Personalis Business Overview
  28. 8.5.3 Personalis Pan-cancer Genomic Profiling Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Personalis Pan-cancer Genomic Profiling Product Portfolio
  30. 8.5.5 Personalis Recent Developments
  31. 8.6 Illumina
  32. 8.6.1 Illumina Company Information
  33. 8.6.2 Illumina Business Overview
  34. 8.6.3 Illumina Pan-cancer Genomic Profiling Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Illumina Pan-cancer Genomic Profiling Product Portfolio
  36. 8.6.5 Illumina Recent Developments
  37. 8.7 Thermo Fisher Scientific
  38. 8.7.1 Thermo Fisher Scientific Company Information
  39. 8.7.2 Thermo Fisher Scientific Business Overview
  40. 8.7.3 Thermo Fisher Scientific Pan-cancer Genomic Profiling Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Thermo Fisher Scientific Pan-cancer Genomic Profiling Product Portfolio
  42. 8.7.5 Thermo Fisher Scientific Recent Developments
  43. 8.8 QIAGEN
  44. 8.8.1 QIAGEN Company Information
  45. 8.8.2 QIAGEN Business Overview
  46. 8.8.3 QIAGEN Pan-cancer Genomic Profiling Revenue and Gross Margin (2021-2026)
  47. 8.8.4 QIAGEN Pan-cancer Genomic Profiling Product Portfolio
  48. 8.8.5 QIAGEN Recent Developments
  49. 8.9 Agilent Technologies
  50. 8.9.1 Agilent Technologies Company Information
  51. 8.9.2 Agilent Technologies Business Overview
  52. 8.9.3 Agilent Technologies Pan-cancer Genomic Profiling Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Agilent Technologies Pan-cancer Genomic Profiling Product Portfolio
  54. 8.9.5 Agilent Technologies Recent Developments
  55. 8.10 SOPHiA GENETICS
  56. 8.10.1 SOPHiA GENETICS Company Information
  57. 8.10.2 SOPHiA GENETICS Business Overview
  58. 8.10.3 SOPHiA GENETICS Pan-cancer Genomic Profiling Revenue and Gross Margin (2021-2026)
  59. 8.10.4 SOPHiA GENETICS Pan-cancer Genomic Profiling Product Portfolio
  60. 8.10.5 SOPHiA GENETICS Recent Developments
  61. 8.11 Sysmex
  62. 8.11.1 Sysmex Company Information
  63. 8.11.2 Sysmex Business Overview
  64. 8.11.3 Sysmex Pan-cancer Genomic Profiling Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Sysmex Pan-cancer Genomic Profiling Product Portfolio
  66. 8.11.5 Sysmex Recent Developments
  67. 8.12 Burning Rock Biotech
  68. 8.12.1 Burning Rock Biotech Company Information
  69. 8.12.2 Burning Rock Biotech Business Overview
  70. 8.12.3 Burning Rock Biotech Pan-cancer Genomic Profiling Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Burning Rock Biotech Pan-cancer Genomic Profiling Product Portfolio
  72. 8.12.5 Burning Rock Biotech Recent Developments
  73. 8.13 Genetron Health
  74. 8.13.1 Genetron Health Company Information
  75. 8.13.2 Genetron Health Business Overview
  76. 8.13.3 Genetron Health Pan-cancer Genomic Profiling Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Genetron Health Pan-cancer Genomic Profiling Product Portfolio
  78. 8.13.5 Genetron Health Recent Developments
  79. 8.14 Geneseeq
  80. 8.14.1 Geneseeq Company Information
  81. 8.14.2 Geneseeq Business Overview
  82. 8.14.3 Geneseeq Pan-cancer Genomic Profiling Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Geneseeq Pan-cancer Genomic Profiling Product Portfolio
  84. 8.14.5 Geneseeq Recent Developments
  85. 8.15 BGI Genomics
  86. 8.15.1 BGI Genomics Company Information
  87. 8.15.2 BGI Genomics Business Overview
  88. 8.15.3 BGI Genomics Pan-cancer Genomic Profiling Revenue and Gross Margin (2021-2026)
  89. 8.15.4 BGI Genomics Pan-cancer Genomic Profiling Product Portfolio
  90. 8.15.5 BGI Genomics Recent Developments
  91. 8.16 Amoy Diagnostics
  92. 8.16.1 Amoy Diagnostics Company Information
  93. 8.16.2 Amoy Diagnostics Business Overview
  94. 8.16.3 Amoy Diagnostics Pan-cancer Genomic Profiling Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Amoy Diagnostics Pan-cancer Genomic Profiling Product Portfolio
  96. 8.16.5 Amoy Diagnostics Recent Developments
  97. 8.17 Roche
  98. 8.17.1 Roche Company Information
  99. 8.17.2 Roche Business Overview
  100. 8.17.3 Roche Pan-cancer Genomic Profiling Revenue and Gross Margin (2021-2026)
  101. 8.17.4 Roche Pan-cancer Genomic Profiling Product Portfolio
  102. 8.17.5 Roche Recent Developments
  103. 8.18 Guardant Health
  104. 8.18.1 Guardant Health Company Information
  105. 8.18.2 Guardant Health Business Overview
  106. 8.18.3 Guardant Health Pan-cancer Genomic Profiling Revenue and Gross Margin (2021-2026)
  107. 8.18.4 Guardant Health Pan-cancer Genomic Profiling Product Portfolio
  108. 8.18.5 Guardant Health Recent Developments
  109. 8.19 Caris Life Sciences
  110. 8.19.1 Caris Life Sciences Company Information
  111. 8.19.2 Caris Life Sciences Business Overview
  112. 8.19.3 Caris Life Sciences Pan-cancer Genomic Profiling Revenue and Gross Margin (2021-2026)
  113. 8.19.4 Caris Life Sciences Pan-cancer Genomic Profiling Product Portfolio
  114. 8.19.5 Caris Life Sciences Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst